Non-surgical management of advanced ovarian cancer with maintenance PARP inhibitors
-
Published:2024-04
Issue:
Volume:52
Page:101340
-
ISSN:2352-5789
-
Container-title:Gynecologic Oncology Reports
-
language:en
-
Short-container-title:Gynecologic Oncology Reports
Author:
Lantsman TaliyaORCID, Jia Lily, Shea Meghan
Reference15 articles.
1. Cancer Facts & Figures 2023;American Cancer Society,2023 2. Arora, S., Balasubramaniam, S., Zhang, H., Berman, T., Narayan, P., Suzman, D., Bloomquist, E., Tang, S., Gong, Y., Sridhara, R., Turcu, F.R., Chatterjee, D., Saritas-Yildirim, B., Ghosh, S., Philip, R., Pathak, A., Gao, J.J., Amiri-Kordestani, L., Pazdur, R., Beaver, J.A., 2021. FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer. Oncologist. 26(1), e164-e172. doi: 10.1002/onco.13551. Epub 2020 Oct 20. PMID: 33017510; PMCID: PMC7794199. 3. Ovarian Real-World International Consortium (ORWIC): A multicentre, real-world analysis of epithelial ovarian cancer treatment and outcomes;Cheeseman;Front. Oncol.,2023 4. Optimal primary surgical treatment for advanced epithelial ovarian cancer;Elattar;Cochrane Database Syst. Rev.,2011 5. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850);Fagotti;Int. J. Gynecol. Cancer,2020
|
|